Torrent Pharma: India Growth Drives 44% Return FY26

Why Torrent Pharma is back on brokerage radars

Torrent Pharmaceuticals is drawing fresh attention from brokerages after a strong set of operating metrics in FY26, led by India and supported by Brazil. The stock has delivered a 44% return over the past year, outperforming peers in the Nifty Pharma universe, especially companies with a high domestic revenue mix. Analysts have pointed to Torrent’s preference for India branded generics, where execution and product mix can support steadier margins than more price-sensitive markets. The near-term triggers highlighted by brokerages include the Q4FY26 performance and May domestic sales. But the more important takeaway for investors is that the growth narrative is being built on chronic therapies and launches rather than one-off factors. Pricing pressure in the US remains a visible headwind in the background, and the company has also taken steps such as discontinuing low-margin products in that market.

Q4FY26: revenue growth led by India, Brazil

In Q4FY26, Torrent was among the few pharma companies to post 16% year-on-year revenue growth on an organic basis, excluding the JB Chemicals acquisition. Growth was described as broad-based across geographies, with India up 15% and Brazil up 17% in the same period. Separately, company commentary around the quarter also cited a 42% rise in consolidated revenue to ₹4,197 crore, alongside strong operating performance. In INR terms, Brazil growth was also referenced at 30% in one management commentary set, underlining the strength in that branded market. Brokerages have repeatedly positioned India as the key driver of consolidated performance, even as the US market faces pricing pressure. The underlying message from multiple notes is that Torrent’s base business is growing faster than the market in its core geographies.

Margin expansion: gross margin improvement and strong EBITDA print

Brokerage commentary flagged that gross margins for the base business improved by 220 basis points year-on-year, indicating better product mix and operating efficiency. Operating profit was reported to be up 16% year-on-year, supporting the view that growth is translating into profitability rather than being bought through higher costs. For Q4FY26, the company’s operating EBITDA increased 41%, with an EBITDA margin of 32.3% cited alongside the ₹4,197 crore revenue figure. Across other FY26 quarters referenced in the data, Torrent’s EBITDA margin remained around the 32% to 33% range, supported by branded market growth and efficiencies. One note cited a gross margin of 75%, led by a stronger geographical mix and the discontinuation of low-margin US products. These margin datapoints matter because Torrent is being compared against a sector that has faced volatility from US pricing, input costs, and uneven domestic demand.

India business: chronic therapies, field force expansion, market outperformance

India remains the central pillar of Torrent’s investment case in brokerage notes, with repeated references to outperformance versus the Indian Pharmaceutical Market (IPM). In Q2FY26, India revenues were reported at ₹1,820 crore, up 12% year-on-year, versus IPM growth of 8%. Another management commentary for Q1 FY26 referenced India revenues of ₹1,811 crore, up 11% year-on-year, again against IPM growth of 8%. Chronic therapies were consistently highlighted as the engine, with traction in cardiac, diabetes, gastro and CNS divisions. Segment data cited cardiac growth of 14%, gastro 15%, and derma 29%, supported by Curatio portfolios. The company is also ranked 7th in the Indian Pharmaceuticals Market and is among the Top 5 in cardiovascular, gastro intestinal, central nervous system, and cosmo-dermatology therapies. Torrent has also expanded its medical representative base, with references to 6,800 MRs as of Q2FY26 (up from 6,600 in the prior quarter) and a plan to reach about 7,000 by FY26-end, while another commentary cited a field force of 7,100 excluding JB.

Brazil and other geographies: branded markets remain the profit anchor

Brokerage notes have emphasised that Brazil is the second major branded growth driver after India. In Q4FY26, Brazil growth was cited at 17% in one organic growth context, while separate company commentary cited 30% growth in INR terms. Branded markets were said to account for 73% of total revenue, positioning the business mix toward markets where portfolio depth and field execution can matter more than commodity-style price competition. Some notes also referred to a sustained recovery in the US business, although the US was described as weaker in certain quarterly discussions. The balance of these points suggests that Torrent’s core investment narrative is still branded markets first, with the US treated as an incremental swing factor rather than the base case.

Product launches and pipeline: semaglutide and India-focused R&D

A recurring theme in the commentary is the importance of new launches, particularly in chronic categories. The introduction of semaglutide was described as successful, with Torrent said to have captured a significant market share in both injectable and oral forms, although no specific share number was provided. Management also indicated a reallocation of R&D budget towards India, highlighting opportunities such as oral semaglutide. Beyond diabetes and metabolic therapies, the company cited a pipeline with multiple first-to-market prospects in India. It also referenced a potential launch of a NASH product following patent expiration, again without specifying timelines. Brokerages expect FY27 momentum to be supported by improved offtake in chronic therapies and the cadence of launches.

JB Chemicals integration: synergy as a growth lever

Brokerages have also flagged cost and revenue synergies from integrating JB Chemicals as a support factor for future growth. While some growth numbers were cited on an “excluding JB Chemicals acquisition” basis to show organic strength, the combined platform is still seen as strategically useful. The expectation articulated in brokerage summaries is that synergies can help sustain margins and widen portfolio reach across key markets. This matters because it provides an additional lever beyond pure volume growth. At the same time, the organic growth references indicate that the market is closely tracking how much of performance comes from execution versus acquisitions.

What the Street is pricing in: ratings and consensus signals

Analyst positioning remains broadly supportive based on the data cited. Of 33 analysts tracking the stock, 25 maintain a ‘buy’ rating, five suggest ‘hold’, and three recommend ‘sell’, as per Bloomberg data referenced in the notes. That distribution indicates positive consensus but not unanimity, reflecting both strength in branded markets and the known challenges in the US. Brokerages also noted Torrent’s outperformance relative to the Nifty Pharma index, linking it to consistent domestic execution and margin resilience. The near-term focus areas remain India growth, Brazil momentum, and whether the company can protect profitability as its mix evolves.

Key numbers investors are tracking

Market impact and why it matters

Torrent’s FY26 narrative has mattered to the market because it combines above-market domestic growth with a margin profile that has stayed robust. The company’s India performance has been repeatedly benchmarked against IPM growth of 8%, with Torrent posting 11% to 12% growth in different quarters cited. That gap, along with growth in Brazil, supports the view that branded market execution is driving incremental profitability. Margin commentary such as the 220 bps base business gross margin improvement and EBITDA margins in the low-30% range has helped brokerages justify the stock’s premium positioning within domestic-heavy pharma names. The US remains a factor due to pricing pressure, and the decision to discontinue low-margin products is relevant for mix improvement. For investors, the key is that brokerages are anchoring the thesis to operating numbers and product-launch led growth rather than only to sentiment.

Conclusion: what to watch into FY27

Torrent Pharma’s position as a brokerage sectoral pick is being reinforced by strong India and Brazil growth, improving margins, and a year of clear stock outperformance. The near-term attention has centred on Q4FY26 execution and domestic sales momentum, while FY27 expectations are tied to chronic therapy offtake and new launches such as semaglutide. Investors will also track how JB Chemicals integration translates into measurable cost and revenue synergies. Street commentary suggests the next set of quarterly updates will be closely watched for sustained branded-market growth and margin stability, especially as US pricing conditions remain uneven.